A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies

Lin, C.-C., Garralda, E., Schöffski, P., Hong, D. S., Siu, L. L., Martin, M., Maur, M., Hui, R., Soo, R. A., Chiu, J., Zhang, T., Ma, B., Kyi, C., Tan, D. S., Cassier, P. A., Sarantopoulos, J., Weickhardt, A., Carvajal, R. D., Spratlin, J., … De Braud, F. (2023). A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies. OncoImmunology, 13(1). https://doi.org/10.1080/2162402x.2023.2290787
Authors:
Chia-Chi Lin
Elena Garralda
Patrick Schöffski
David S Hong
Lillian L Siu
Miguel Martin
Michela Maur
Rina Hui
Ross A Soo
Joanne Chiu
Tian Zhang
Brigette Ma
Chrisann Kyi
Daniel Sw Tan
Philippe A Cassier
John Sarantopoulos
Andrew Weickhardt
Richard D Carvajal
Jennifer Spratlin
Taito Esaki
Fréderic Rolland
Wallace Akerley
Barbara Deschler-Baier
Lawrence Rispoli
Tanay S Samant
Niladri Roy Chowdhury
Daniel Gusenleitner
Eunice L Kwak
Vasileios Askoxylakis
Filippo De Braud
Affiliated Authors:
Richard D Carvajal
Columbia Affiliation:
Subjects:
Cancer Immunotherapy (OpenAlex Topic)
Chimeric Antigen Receptor T Cell Therapy (OpenAlex Topic)
Malignant Pleural Mesothelioma Research (OpenAlex Topic)
Carcinoma, Non-Small-Cell Lung (MeSH)
Melanoma (MeSH)
Carcinoma, Renal Cell (MeSH)
Lung Neoplasms (MeSH)
Kidney Neoplasms (MeSH)
Exanthema (MeSH)
Author Keywords:
efficacy
ieramilimab
lag-3 inhibitor
safety
spartalizumab
elink
Publication Type:
Article
Unique ID:
10.1080/2162402x.2023.2290787
PMID:
38170160
DOI:
10.1080/2162402x.2023.2290787
Journal:
OncoImmunology
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View OpenAlex Record
View Web of Science Record

Record Created: